Dataset Information


Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.

ABSTRACT: CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) plays a crucial role in the stability of the programmed death-ligand 1 (PD-L1). However, there has been no previous study of CMTM6 in non-small cell lung cancer (NSCLC) and its association with PD-L1 has not been confirmed. The aim of this study was to investigate the expression of CMTM6 and PD-L1 and to confirm their predictive roles for anti-PD-1 therapy in non-small cell lung cancer. CMTM6 and PD-L1 immunohistochemical expressions were evaluated in 35 advanced, treatment-refractory NSCLC patients who received PD-1 inhibitor therapy. The correlation between CMTM6 and PD-L1 expression was also determined based on immunohistochemistry and RNA-sequencing data obtained from The Cancer Genome Atlas (TCGA) database. CMTM6 expression was positively correlated with PD-L1 expression in immunohistochemical data (Pearson's r = 0.342 and p = .044). A positive correlation was also identified in the mRNA expression data. Using receiver operating characteristic curves, the levels of CMTM6 and PD-L1 expression which provided the best distinguishing point between responder versus non-responder to PD-1 inhibitors were 70 and 75 H-scores, respectively. The patients in the PD-1 inhibitor responder group had higher CMTM6 expressions in univariate logistic regression analysis (odds ratio (OR) = 5.333, p = .037). However, PD-L1 expression was not associated with response to PD-1 inhibitor (p = .288). In multivariate analysis, CMTM6 was also found to be an independent predictor of the response to PD-1 inhibitors (OR = 6.226, p = .032). CMTM6 expression can be a promising predictor useful for therapeutic decision-making regarding PD-1 inhibitors.


PROVIDER: S-EPMC6791430 | BioStudies | 2019-01-01

SECONDARY ACCESSION(S): 10.20892/j.issn.2095-3941.2016.0009

REPOSITORIES: biostudies

altmetric image


Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?

Mino-Kenudson Mari M  

Cancer biology & medicine 20160601 2

Blockade of immune checkpoints has recently emerged as a novel therapeutic strategy in various tumors. In particular, monoclonal antibodies targeting programmed cell death 1 (PD-1) or its ligand (PD-L1) have been most studied in lung cancer, and PD-1 inhibitors are now established agents in the management of non-small cell lung cancer (NSCLC). The reports on high-profile clinical trials have shown the association of PD-L1 expression by immunohistochemistry (IHC) with higher overall response rate  ...[more]

Similar Datasets

2020-01-01 | S-EPMC7300202 | BioStudies
2020-01-01 | S-EPMC7439957 | BioStudies
2019-01-01 | S-EPMC6951804 | BioStudies
2017-01-01 | S-EPMC6333292 | BioStudies
2017-01-01 | S-EPMC5706633 | BioStudies
2019-01-01 | S-EPMC6804456 | BioStudies
2018-01-01 | S-EPMC6156716 | BioStudies
2020-01-01 | S-EPMC7291156 | BioStudies
2018-01-01 | S-EPMC5919255 | BioStudies
2020-01-01 | S-EPMC7458663 | BioStudies